Date: 2018-09-10
Type of information: Licensing agreement
Compound: Nanofitin®-conjugated biotherapeutics
Company: Affilofic (France) Samabriva (France)
Therapeutic area: Rare diseases - Genetic diseases - Metabolic diseases
Type agreement: licensing
Action mechanism:
- antibody mimetic. Nanofitins® are potent antibody-mimetics, exhibiting high affinity and specificity for capture, targeting and interaction with biomolecules. They can be easily conjugated to other moieties, such as antibodies, small molecules, and nanoparticles, to empower third parties’ molecules, their very small size triggering low impact on the natural properties of such payload. Deriving from a naturally hyperstable scaffold, Nanofitins® are resistant to temperature and pH, stable to proteases, spontaneously refolding. They are produced by simple, scalable, GMPcompliant
bacterial fermentation at very attractive costs or by chemical synthesis.
Affilogic has designed Nanofitins® against 50+ targets to date, including a wide range of circulating antigens (peptides, proteins), membrane receptors for inhibition / modulation / translocation, and complex entities (Virus-like Particles, bacteria, whole cells).
Disease: lysosomal storage disorders
Details:
- • On September 10, 2018, Samabriva and Affilogic announced that they recently entered into an option and license agreement to develop biotherapeutics for the treatment of patients with lysosomal storage disorders. Within this agreement, Samabriva will use Affilogic’s proprietary Nanofitins® technology to develop new therapies to address strong unmet needs in these patients such as the associated neurological damages.
- In the framework of a research collaboration initiated in 2016, Samabriva will pursue the evaluation of Nanofitin®
candidates selected by Affilogic from their proprietary libraries in combination with lysosomal enzymes. The
partners will combine research efforts to optimize such Nanofitin®-conjugated biotherapeutics in order to satisfy
unmet medical needs in the treatment of patients with Lysosomal Storage Disorders. Samabriva will have sole
responsibility for their evaluation, preclinical and clinical developments. Samabriva will be entitled to
commercialize worldwide products incorporating Affilogic Nanofitins® resulting from the collaboration to treat
Lysosomal Storage Disorders.
- Samabriva's lead drug candidate, SAM-01, is an original acid-sphingomyelinase recombinant enzyme for Niemann-Pick disease, with enhances features such as a unique joint targeting of peripheral and neurological diseased
and extended half-life.
Financial terms:
- Under the terms of the agreement, Affilogic will receive an upfront payment and is eligible to receive further research funding, milestones payments and royalties by Samabriva. Further details of the agreement were not disclosed.
Latest news:
Is general: Yes
